Genome editing in cancer: Challenges and potential opportunities

Dor Breier; Dan Peer

doi:10.1016/j.bioactmat.2022.08.013

Genome editing in cancer: Challenges and potential opportunities

Dor Breier, Dan Peer^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for in-vivo therapies, including off-target activity and the effects of the double strand break induction on genomic stability. Here, we will focus on the inherent challenges in the CRISPR/Cas9 system and discuss various opportunities to overcoming these challenges.

Original language	English
Pages (from-to)	394-402
Number of pages	9
Journal	Bioactive Materials
Volume	21
DOIs	https://doi.org/10.1016/j.bioactmat.2022.08.013
State	Published - Mar 2023

Keywords

CRISPR/Cas systems
Cancer therapy
Genome editing
Off-target activity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bioactmat.2022.08.013

Cite this

@article{158c2496fa254fe7a48e15987a66ed82,

title = "Genome editing in cancer: Challenges and potential opportunities",

abstract = "Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for in-vivo therapies, including off-target activity and the effects of the double strand break induction on genomic stability. Here, we will focus on the inherent challenges in the CRISPR/Cas9 system and discuss various opportunities to overcoming these challenges.",

keywords = "CRISPR/Cas systems, Cancer therapy, Genome editing, Off-target activity",

author = "Dor Breier and Dan Peer",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = mar,

doi = "10.1016/j.bioactmat.2022.08.013",

language = "אנגלית",

volume = "21",

pages = "394--402",

journal = "Bioactive Materials",

issn = "2452-199X",

publisher = "KeAi Communications Co.",

}

TY - JOUR

T1 - Genome editing in cancer

T2 - Challenges and potential opportunities

AU - Breier, Dor

AU - Peer, Dan

PY - 2023/3

Y1 - 2023/3

N2 - Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for in-vivo therapies, including off-target activity and the effects of the double strand break induction on genomic stability. Here, we will focus on the inherent challenges in the CRISPR/Cas9 system and discuss various opportunities to overcoming these challenges.

AB - Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for in-vivo therapies, including off-target activity and the effects of the double strand break induction on genomic stability. Here, we will focus on the inherent challenges in the CRISPR/Cas9 system and discuss various opportunities to overcoming these challenges.

KW - CRISPR/Cas systems

KW - Cancer therapy

KW - Genome editing

KW - Off-target activity

UR - http://www.scopus.com/inward/record.url?scp=85138055258&partnerID=8YFLogxK

U2 - 10.1016/j.bioactmat.2022.08.013

DO - 10.1016/j.bioactmat.2022.08.013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36185740

AN - SCOPUS:85138055258

SN - 2452-199X

VL - 21

SP - 394

EP - 402

JO - Bioactive Materials

JF - Bioactive Materials

ER -

Genome editing in cancer: Challenges and potential opportunities

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this